Movalis (Meloxicam)

Meloxicam works by selectively blocking the cyclooxygenase‑2 (COX‑2) enzyme, which reduces the production of prostaglandins—chemicals that trigger inflammation, pain, and fever. By sparing COX‑1, it maintains protective gastric prostaglandins while delivering anti‑inflammatory and analgesic effects.

The appropriate dose of Movalis is determined by the prescribing healthcare professional based on the individual’s condition, severity of symptoms, age, renal and hepatic function, and other clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of meloxicam in pregnancy or while breastfeeding has not been definitively established. It is generally advised to avoid NSAIDs, including meloxicam, during the third trimester of pregnancy and to discuss potential risks with a healthcare provider before using it while pregnant or nursing.

To order Movalis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with non‑selective NSAIDs, meloxicam offers a higher degree of COX‑2 selectivity, which may lower the risk of gastrointestinal irritation while still providing effective pain relief. However, cardiovascular and renal safety considerations remain similar to other NSAIDs, and choice of therapy should be individualized.

Movalis should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Movalis is taken orally, usually with a full glass of water. It may be taken with or without food, but taking it with food can help reduce possible stomach upset. The exact administration schedule is set by the prescriber.

Serious risks include gastrointestinal bleeding or ulceration, cardiovascular events such as heart attack or stroke, severe liver injury, kidney impairment, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they notice signs of these conditions.

Movalis should be avoided in individuals with known hypersensitivity to meloxicam or other NSAIDs, active gastrointestinal ulceration, severe heart failure, uncontrolled hypertension, and those who have had recent coronary artery bypass graft surgery. It is also contraindicated in patients with significant renal or hepatic impairment unless specifically advised by a physician.